Product Center
Ab&B Bio-exhibition wrapped up successfully
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-04-23
- Views:
(Summary description)From April 20 to 21, 2024, the National Conference on Vaccines and Health was held in Xiong'an, Hebei Province, with the theme of “Standardize-Expand-Innovate-Promote the Construction of a Healthy China with High-Quality Immunization Services”, focusing on the scientific and practical issues involved in the high-quality development of vaccine immunization services and discussing optimization strategies.
Ab&B Bio-exhibition wrapped up successfully
(Summary description)From April 20 to 21, 2024, the National Conference on Vaccines and Health was held in Xiong'an, Hebei Province, with the theme of “Standardize-Expand-Innovate-Promote the Construction of a Healthy China with High-Quality Immunization Services”, focusing on the scientific and practical issues involved in the high-quality development of vaccine immunization services and discussing optimization strategies.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-04-23 10:20
- Views:
From April 20 to 21, 2024, the National Conference on Vaccines and Health was held in Xiong'an, Hebei Province, with the theme of “Standardize-Expand-Innovate-Promote the Construction of a Healthy China with High-Quality Immunization Services”, focusing on the scientific and practical issues involved in the high-quality development of vaccine immunization services and discussing optimization strategies. The conference focused on the scientific and practical issues involved in the high-quality development of vaccine immunization services, exchanged research results, shared practical experience and discussed optimization strategies.
Ab&B Bio-Tech CO.,LTD.JS participated in the exhibition with the first quadrivalent influenza virus subunit vaccine (HRK-X®) in China. During the meeting, the staff made a detailed introduction of the company and its products to the experts and scholars from medical and healthcare institutions, research institutes, colleges and universities at all levels in China, and introduced the characteristics of the subunit influenza vaccine, which extracts only the effective antigens, hemagglutinin and neuraminidase, through the model of the influenza virus, which gained the attention and favor of all of them.
This conference set up a number of conferences and sessions in parallel, such as 50 Years of Global EPI - The Road to China, in which more than 160 renowned experts from China shared their academic achievements on the hot issues in the fields of vaccine research and development, vaccination prevention, disease prevention and control, and so on. Among them, in the session report on “Progress and Application of Vaccine Clinical Trials”, Director Pan Hongxing from the Vaccine Clinical Evaluation Institute of Jiangsu CDC, with the theme of “Progress of Clinical Evaluation of New Domestic Influenza Vaccine”, introduced the current situation of influenza vaccine application in China and around the world, and the stage-by-stage safety data of Phase III clinical study of the new domestic tetravalent subunit influenza vaccine and the scientific research topic of the National Center for Evaluation.
Relevant information
-
Influenza virus subunit vaccine (adjuvant) IND application approvedRecently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) jointly applied for a Class I new drug "Influenza Virus Subunit Vaccine (Adjuvant)" IND application, which has been approved by the Drug Evaluation Center (CDE) of the China National Medical Products Administration. The approval of this vaccine marks the completion of the full coverage of the company's subunit influenza vaccine product pipeline for trivalent and quadrivalent influenza virus subunit vaccines, providing the most accurate selection for different age groups and different demand groups. - The application for the marketing of trivalent influenza virus subunit vaccine has been accepted! 10-08
- Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants 08-26
- Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
